-Reuters
Silence Therapeutics Announces Topline Data In SLN360 Phase 1 Single-Ascending Dose Study In Healthy Adults With High Lipoprotein(a)
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (“siRNA”)